Takeda and pfizer announce four-year results from positive phase 3 hd21 trial of additional adcetris® (brentuximab vedotin) combination in frontline hodgkin lymphoma

Osaka, japan & cambridge, mass. & new york--(business wire)--takeda (tse:4502/nyse:tak) and pfizer (nyse: pfe) today announced that the german hodgkin study group (ghsg) will present positive results from the phase 3 hd21 trial evaluating adcetris® (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th american society of clinical oncology (asco) annual meeting (lba7000) and at the 29th european hematology association (eha) annual meeting (s225).
TAK Ratings Summary
TAK Quant Ranking